Pharma Update
Important launches ahead in Diagnostics
Diagnostics to deliver mid to high single digit growth in coming years
Core & Molecular Lab
Mass spectrometry
Continuous glucose
monitoring (CGM)
Next generation
sequencing (NGS)
Clinical
Chemistry
Immuno
Chemistry
Mass
Spectrometry
102
>50X Expansion
Roche
.
• Menu expansion driving growth,
averaging >25 assay
launches/approvals per year¹
• >240 assays running on >100k
installed cobasⓇ serum work area
instruments
>2.5k installed cobas® 6800/8800/
5800 instruments
•
⚫ First fully integrated and
automated mass spectrometry
•
Launch menu complimentary to
immunoassay offering, including
>40 key parameters at launch
• CE launch planned for end of 2024
(FDA approval expected in 2025)
•
.
Subcutaneously inserted sensor to
measure glucose values in
interstitial fluid
Personalized management of
diabetes
Digital tools to support disease
management for users and
healthcare professionals
•
•
Unique sequencing by expansion
technology, significantly
improving nanopore performance
Nanopore system delivers flexible
run size at competitive cost
1. average 2018-2022; excludes claim extensions for new instruments, excludes Biotin updated assays, COVID-19, Custom Biotech, TiB Molbiol & Genmark, RUOS, IVDR transitions; CGM-continuous glucose monitoring;
NGS=next generation sequencing
17View entire presentation